SCHEMBL257272

SCHEMBL257272

COc1ccc(C(=O)c2ccc(C)c(Cl)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.64
MAPT P10636 7/20 0.59
ALDH1A1 P00352 4/20 0.59
LMNA P02545 3/20 0.59
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
MAPK1 P28482 3/20 0.58
RAF1 P04049 1/20 0.58
GFER P55789 1/20 0.58
PAX8 Q06710 1/20 0.58
GAA P10253 2/20 0.58
RAB9A P51151 2/20 0.56
NPSR1 Q6W5P4 2/20 0.54
POLB P06746 2/20 0.54
KCNH2 Q12809 1/20 0.54
ATM Q13315 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
TUBB4A P04350 1/20 0.53
TUBB P07437 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4743799 0.86 HPGD (0.68) HPGDMAPTALDH1A1LMNAKMT2A
SCHEMBL15100601 0.86 KMT2A (0.57) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL2924706 0.86 HPGD (0.54) HPGDMAPTALDH1A1LMNAKMT2A
SCHEMBL11357829 0.84 HTT (0.65) HPGDMAPTALDH1A1LMNAKMT2A
SCHEMBL11095128 0.83 ALDH1A1 (0.73) HPGDMAPTALDH1A1LMNAKMT2A
SCHEMBL11575372 0.83 TUBB4A (0.60) HPGDMAPTALDH1A1LMNAKMT2A
SCHEMBL257653 0.82 ALDH1A1 (0.61) HPGDMAPTALDH1A1LMNARAB9A
SCHEMBL15100942 0.82 SRD5A2 (0.53) HPGDMAPTALDH1A1LMNAMAPK1
SCHEMBL257513 0.81 FABP2 (0.46) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL11313816 0.81 ALDH1A1 (0.75) HPGDMAPTALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 HPGD 3711/4885MAPT 3973/4885ALDH1A1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.